Stay Ahead of the Game With Medtronic (MDT) Q2 Earnings: Wall Street's Insights on Key Metrics

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.31 per share, a 4% increase year-over-year, with revenues projected at $8.86 billion, reflecting a 5.4% increase from the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts project 'Net Sales- World Wide Revenue- Diabetes' at $749.45 million, a 9.3% increase year-over-year [5] - 'Net Sales- World Wide Revenue- Neuroscience' is expected to reach $2.49 billion, reflecting a 1.5% increase from the prior year [5] - 'Net Sales- World Wide Revenue- Cardiovascular' is forecasted at $3.36 billion, indicating an 8.5% increase year-over-year [6] - 'Net Sales- World Wide Revenue- Medical Surgical' is anticipated to be $2.24 billion, a 5.4% increase from the previous year [6] - 'Net Sales- U.S. Revenue' is projected at $4.53 billion, reflecting a 5.3% increase year-over-year [6] Specific Segment Estimates - 'Net Sales- U.S. Revenue- Medical Surgical' is expected to be $938.99 million, showing a slight decline of 0.5% year-over-year [7] - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is projected at $351.65 million, a 5.6% increase from the prior year [7] - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is estimated at $326.68 million, indicating a 6.1% increase year-over-year [7] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is expected to be $319.41 million, reflecting a minimal change of +0.1% year-over-year [8] - 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' is projected at $1.03 billion, indicating a 5.4% increase year-over-year [9] - 'Net Sales- ROW- Cardiovascular' is expected to reach $1.80 billion, reflecting a 7.8% increase from the prior year [9] Stock Performance - Over the past month, Medtronic shares have returned +0.5%, compared to the Zacks S&P 500 composite's +4.6% change, suggesting that MDT is likely to perform in line with the overall market [9]